VanEck Pharmaceutical ETF
110 hedge funds and large institutions have $387M invested in VanEck Pharmaceutical ETF in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 11 closing their positions.
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
8% more funds holding
Funds holding: 102 → 110 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $405M → $387M (-$17.9M)
8% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 37
7.53% less ownership
Funds ownership: 94.91% → 87.37% (-7.5%)
72% less call options, than puts
Call options by funds: $1.16M | Put options by funds: $4.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VV
Verity & Verity
Beaufort,
South Carolina
|
+$7.49M |
| 2 |
AC
Avestar Capital
New York
|
+$4.13M |
| 3 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
+$3.88M |
| 4 |
GIA
Gladstone Institutional Advisory
Palm Beach Gardens,
Florida
|
+$3.68M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$19.7M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$11.8M |
| 3 |
AF
Alerus Financial
Grand Forks,
North Dakota
|
-$6.73M |
| 4 |
JP Morgan Chase
New York
|
-$3.53M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3.4M |
PPH Hedge Fund Activity: Q4 2023 in Review
110 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2023, worth a combined $387M — down 4.4% from $405M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PPH positions and 11 closed out — a net gain of 9 holders — while 34 added to existing stakes and 37 trimmed.
The largest buyer was Verity & Verity, opening a new position worth an estimated $7.49M. The largest seller was Goldman Sachs, cutting an estimated $19.7M.
- 110 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2023, up from 102 in Q3 2023.
- Funds reported $387M of VanEck Pharmaceutical ETF stock for Q4 2023, down 4.4% quarter-over-quarter.
- 20 funds opened new VanEck Pharmaceutical ETF positions in Q4 2023 and 11 closed out, a net change of +9 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2023 was Verity & Verity, an estimated $7.49M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2023 was Goldman Sachs, an estimated $19.7M sold.
Based on aggregated 13F filings for Q4 2023.